Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Therapeutic inhibition of GAS6-AS1/YBX1/MYC axis suppresses cell propagation and disease progression of acute myeloid leukemia

Fig. 1

GAS6-AS1 is overexpressed in bone marrow of AML patients and AML cell lines, and is related to poor prognosis. A Hierarchical clustering analysis of differentially expressed lncRNAs (fold change > 2; P < 0.05) in AML and normal bone marrow mononuclear cells. B Overlap of misregulated lncRNAs in GEO datasets. C Analysis and comparison of GAS6-AS1 gene expression in cell lines of different tissue origins in the Cancer Cell Line Encyclopedia (CCLE) database. D Analyses of GAS6-AS1 expression levels in AML and other cancers using The Cancer Genome Atlas (TCGA) database. ACC, Adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, Stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma. E Comparing the expression levels of GAS6-AS1 between AML and normal controls (TCGA vs GETx). F GAS6-AS1 expression was examined by qRT-PCR in AML (n = 78) and normal bone marrow mononuclear cells (n = 20). G, H, I Kaplan–Meier survival analysis of overall survival in AML patients, separately in three independent cohorts (IHUH, TCGA and GSE37642). Data were depicted as mean ± s.e.m., *P < 0.05

Back to article page